3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients-Reference-Cited by-同舟云学术

3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

Published:2018-02 Issue: Volume:90 Page:102-110
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Verly I.R.N.,van Kuilenburg A.B.P.,Abeling N.G.G.M.,Goorden S.M.I.,Fiocco M.,Vaz F.M.,van Noesel M.M.,Zwaan C.M.,Kaspers G.J.L.,Merks J.H.M.,Caron H.N.,Tytgat G.A.M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference34 articles.

1. Neuroblastoma: biology, prognosis, and treatment;Park;Hematol Oncol Clin North Am,2010

2. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers;Oberthuer;Clin Cancer Res,2015

3. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment;Brodeur;J Clin Oncol,1993

4. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report;Cohn;J Clin Oncol,2009

5. Significance of catecholamine excretion in the follow-up of sympathoblastomas;Barontini de;Cancer,1971

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison Between Twenty-Four-Hour Collection and Single Spot Urines for the Detection of Biogenic Amines by High-Performance Liquid Chromatography Tandem Mass Spectrometry;Journal of Clinical Medicine Research;2024-06

2. Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations;Cancer Science;2024-02-27

3. Optimising urinary catecholamine metabolite diagnostics for neuroblastoma;Pediatric Blood & Cancer;2023-04-03

4. Nucleolin expression has prognostic value in neuroblastoma patients;eBioMedicine;2022-11

5. Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma;JCO Precision Oncology;2022-05